Viatris (VTRS) Profit After Tax (QoQ) (2020 - 2026)
Viatris (VTRS) Profit After Tax (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -167.35% |
| Mar 31, 2026 | 151.87% |
| Dec 31, 2025 | -165.29% |
| Sep 30, 2025 | -2,686.96% |
| Jun 30, 2025 | 99.85% |
| Mar 31, 2025 | -488.96% |
| Dec 31, 2024 | -644.83% |
| Sep 30, 2024 | 129.04% |
| Jun 30, 2024 | -386.57% |
| Mar 31, 2024 | 114.88% |
| Dec 31, 2023 | -330.88% |
| Sep 30, 2023 | 25.61% |
| Jun 30, 2023 | 17.49% |
| Mar 31, 2023 | -77.78% |
| Dec 31, 2022 | 185.41% |
| Sep 30, 2022 | 12.87% |
| Jun 30, 2022 | -21.37% |
| Mar 31, 2022 | 251.33% |
| Dec 31, 2021 | -184.69% |
| Sep 30, 2021 | 211.57% |